Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 4/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8481267 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL805381 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13646399 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10274569 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13646425 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL358679 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL358271 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14345941 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12899391 | 0.96 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13806911 | 0.96 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063154-B1 | CROSS-COUPLING OF UNACTIVATED SECONDARY BORONIC ACIDS | UNIV ILLINOIS (US) | 2023-08-30 | — | — | EP | disclosed |
| US-9718788-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9458108-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9289383-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160039761-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9150525-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150183753-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2007138110-A2 | COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY | DEVGEN N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2006111549-A1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183753-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | PSEN1 139/4885PSEN2 503/4885APH1B 192/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PSEN1 2098/4885PSEN2 3311/4885APH1B 374/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | PSEN1 2957/4885PSEN2 3933/4885APH1B 3563/4885 |
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | RCE1, ECE1, UBE2E1 | PSEN1 139/4885PSEN2 503/4885APH1B 192/4885 |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | PSEN1 2002/4885PSEN2 1057/4885APH1B 3764/4885 |
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | PSEN1 3687/4885PSEN2 4320/4885APH1B 2807/4885 |
| US-20160039761-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | PSEN1 139/4885PSEN2 503/4885APH1B 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.